56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Watch Crinetics Pharmaceuticals' latest callCrinetics Pharmaceuticals (NASDAQ:CRNX) Q1 2026 Earnings Call · Replay · May 7Read the transcript of Crinetics Pharmaceuticals (NASDAQ:CRNX) Q1 2026 Earnings CallCrinetics Pharmaceuticals, Inc. on 6ix
In the deck
Story so far
Earlier from Crinetics Pharmaceuticals
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Later from Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
- Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
- Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Follow Crinetics Pharmaceuticals into a list and get an email when it puts out news.
Follow Crinetics Pharmaceuticals